Abstract
Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. Design and Methods: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as
| Original language | English |
|---|---|
| Pages (from-to) | 1792-1796 |
| Number of pages | 5 |
| Journal | Haematologica |
| Volume | 93 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2008 |
Fingerprint
Keywords
- Blast crisis
- Chronic myeloid leukemia
- Imatinib
- Long-term
- Outcome
ASJC Scopus subject areas
- Hematology
Cite this
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg : Outcome of the patients alive after a 6-year follow-up. / Palandri, Francesca; Castagnetti, Fausto; Testoni, Nicoletta; Luatti, Simona; Marzocchi, Giulia; Bassi, Simona; Breccia, Massimo; Alimena, Giuliana; Pungolino, Ester; Rege-Cambrin, Giovanna; Varaldo, Riccardo; Miglino, Maurizio; Specchia, Giorgina; Zuffa, Eliana; Ferrara, Felicetto; Bocchia, Monica; Saglio, Giuseppe; Pane, Fabrizio; Alberti, Daniele; Martinelli, Giovanni; Baccarani, Michele; Rosti, Gianantonio.
In: Haematologica, Vol. 93, No. 12, 12.2008, p. 1792-1796.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg
T2 - Outcome of the patients alive after a 6-year follow-up
AU - Palandri, Francesca
AU - Castagnetti, Fausto
AU - Testoni, Nicoletta
AU - Luatti, Simona
AU - Marzocchi, Giulia
AU - Bassi, Simona
AU - Breccia, Massimo
AU - Alimena, Giuliana
AU - Pungolino, Ester
AU - Rege-Cambrin, Giovanna
AU - Varaldo, Riccardo
AU - Miglino, Maurizio
AU - Specchia, Giorgina
AU - Zuffa, Eliana
AU - Ferrara, Felicetto
AU - Bocchia, Monica
AU - Saglio, Giuseppe
AU - Pane, Fabrizio
AU - Alberti, Daniele
AU - Martinelli, Giovanni
AU - Baccarani, Michele
AU - Rosti, Gianantonio
PY - 2008/12
Y1 - 2008/12
N2 - Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. Design and Methods: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as
AB - Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. Design and Methods: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as
KW - Blast crisis
KW - Chronic myeloid leukemia
KW - Imatinib
KW - Long-term
KW - Outcome
UR - http://www.scopus.com/inward/record.url?scp=57349124075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57349124075&partnerID=8YFLogxK
U2 - 10.3324/haematol.13068
DO - 10.3324/haematol.13068
M3 - Article
C2 - 18838477
AN - SCOPUS:57349124075
VL - 93
SP - 1792
EP - 1796
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 12
ER -